Expandable medical device with S-shaped bridging elements

Abstract
An expandable medical device includes a plurality of cylindrical tubes each formed of a plurality of adjacent struts interconnected at alternating ends. The plurality of cylindrical tubes are expandable from a first diameter to a second diameter at which the adjacent struts form substantially V-shapes. The plurality of cylindrical tubes are arranged with the interconnected ends of the struts aligned facing each other in adjacent cylindrical tubes and a plurality of S-shaped bridging elements connected between the interconnected ends of the struts in adjacent cylindrical tubes. The bridging elements are connected entirely above a midline of the V-shapes on one cylindrical tube and entirely below the midline of the V-shapes on an adjacent cylindrical tube.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to tissue-supporting medical devices, and more particularly to expandable, non-removable devices that are implanted within a bodily lumen of a living animal or human to support the organ and maintain patency.


2. Summary of the Related Art


In the past, permanent or biodegradable devices have been developed for implantation within a body passageway to maintain patency of the passageway. These devices are typically introduced percutaneously, and transported transluminally until positioned at a desired location. These devices are then expanded either mechanically, such as by the expansion of a mandrel or balloon positioned inside the device, or expand themselves by releasing stored energy upon actuation within the body. Once expanded within the lumen, these devices, called stents, become encapsulated within the body tissue and remain a permanent implant.


Known stent designs include monofilament wire coil stents (U.S. Pat. No. 4,969,458); welded metal cages (U.S. Pat. Nos. 4,733,665 and 4,776,337); and, most prominently, thin-walled metal cylinders with axial slots formed around the circumference (U.S. Pat. Nos. 4,733,665, 4,739,762, and 4,776,337). Known construction materials for use in stents include polymers, organic fabrics and biocompatible metals, such as, stainless steel, gold, silver, tantalum, titanium, and shape memory alloys such as Nitinol.


U.S. Pat. Nos. 4,733,665, 4,739,762, and 4,776,337 disclose expandable and deformable interluminal vascular grafts in the form of thin-walled tubular members with axial slots allowing the members to be expanded radially outwardly into contact with a body passageway. After insertion, the tubular members are mechanically expanded beyond their elastic limit and thus permanently fixed within the body. The force required to expand these tubular stents is proportional to the thickness of the wall material in a radial direction. To keep expansion forces within acceptable levels for use within the body (e.g., 5-10 atm), these designs must use very thin-walled materials (e.g., stainless steel tubing with 0.0025 inch thick walls). However, materials this thin are not visible on conventional fluoroscopic and x-ray equipment and it is therefore difficult to place the stents accurately or to find and retrieve stents that subsequently become dislodged and lost in the circulatory system.


Further, many of these thin-walled tubular stent designs employ networks of long, slender struts whose width in a circumferential direction is two or more times greater than their thickness in a radial direction. When expanded, these struts are frequently unstable, that is, they display a tendency to buckle, with individual struts twisting out of plane. Excessive protrusion of these twisted struts into the bloodstream has been observed to increase turbulence, and thus encourage thrombosis. Additional procedures have often been required to attempt to correct this problem of buckled struts. For example, after initial stent implantation is determined to have caused buckling of struts, a second, high-pressure balloon (e.g., 12 to 18 atm) would be used to attempt to drive the twisted struts further into the lumen wall. These secondary procedures can be dangerous to the patient due to the risk of collateral damage to the lumen wall.


Many of the known stents display a large elastic recovery, known in the field as “recoil,” after expansion inside a lumen. Large recoil necessitates over-expansion of the stent during implantation to achieve the desired final diameter. Over-expansion is potentially destructive to the lumen tissue. Known stents of the type described above experience recoil of up to about 6 to 12% from maximum expansion.


Large recoil also makes it very difficult to securely crimp most known stents onto delivery catheter balloons. As a result, slippage of stents on balloons during interlumenal transportation, final positioning, and implantation has been an ongoing problem. Many ancillary stent securing devices and techniques have been advanced to attempt to compensate for this basic design problem. Some of the stent securing devices include collars and sleeves used to secure the stent onto the balloon.


Another problem with known stent designs is non-uniformity in the geometry of the expanded stent. Non-uniform expansion can lead to non-uniform coverage of the lumen wall creating gaps in coverage and inadequate lumen support. Further, over expansion in some regions or cells of the stent can lead to excessive material strain and even failure of stent features. This problem is potentially worse in low expansion force stents having smaller feature widths and thicknesses in which manufacturing variations become proportionately more significant. In addition, a typical delivery catheter for use in expanding a stent includes a balloon folded into a compact shape for catheter insertion. The balloon is expanded by fluid pressure to unfold the balloon and deploy the stent. This process of unfolding the balloon causes uneven stresses to be applied to the stent during expansion of the balloon due to the folds causing the problem non-uniform stent expansion.


U.S. Pat. No. 5,545,210 discloses a thin-walled tubular stent geometrically similar to those discussed above, but constructed of a nickel-titanium shape memory alloy (“Nitinol”). This design permits the use of cylinders with thicker walls by making use of the lower yield stress and lower elastic modulus of martensitic phase Nitinol alloys. The expansion force required to expand a Nitinol stent is less than that of comparable thickness stainless steel stents of a conventional design. However, the “recoil” problem after expansion is significantly greater with Nitinol than with other materials. For example, recoil of a typical design Nitinol stent is about 9%. Nitinol is also more expensive, and more difficult to fabricate and machine than other stent materials, such as stainless steel.


All of the above stents share a critical design property: in each design, the features that undergo permanent deformation during stent expansion are prismatic, i.e., the cross sections of these features remain constant or change very gradually along their entire active length. To a first approximation, such features deform under transverse stress as simple beams with fixed or guided ends: essentially, the features act as a leaf springs. These leaf spring like structures are ideally suited to providing large amounts of elastic deformation before permanent deformation commences. This is exactly the opposite of ideal stent behavior. Further, the force required to deflect prismatic stent struts in the circumferential direction during stent expansion is proportional to the square of the width of the strut in the circumferential direction. Expansion forces thus increase rapidly with strut width in the above stent designs. Typical expansion pressures required to expand known stents are between about 5 and 10 atmospheres. These forces can cause substantial damage to tissue if misapplied.



FIG. 1 shows a typical prior art “expanding cage” stent design. The stent 10 includes a series of axial slots 12 formed in a cylindrical tube 14. Each axial row of slots 12 is displaced axially from the adjacent row by approximately half the slot length providing a staggered slot arrangement. The material between the slots 12 forms a network of axial struts 16 joined by short circumferential links 18. The cross section of each strut 16 remains constant or varies gradually along the entire length of the strut and thus the rectangular moment of inertia and the elastic and plastic section moduli of the cross section also remain constant or vary gradually along the length of the strut. Such a strut 16 is commonly referred to as a prismatic beam. Struts 16 in this type of design are typically 0.005 to 0.006 inches (0.127-0.1524 mm) wide in the circumferential direction. Strut thicknesses in the radial direction are typically about 0.0025 inches (0.0635 mm) or less to keep expansion forces within acceptable levels. However, most stent materials must be approximately 0.005 inches (0.127 mm) thick for good visibility on conventional fluoroscopic equipment. This high ratio of strut width to thickness, combined with the relatively high strut length and the initial curvature of the stent tubing combine to cause the instability and bucking often seen in this type of stent design. When expanded, the stent structure of FIG. 1 assumes the roughly diamond pattern commonly seen in expanded sheet metal.


Another stent described in PCT publication number WO 96/29028 uses struts with relatively weak portions of locally-reduced cross sections which on expansion of the stent act to concentrate deformation at these areas. However, as discussed above non-uniform expansion is even more of a problem when smaller feature widths and thicknesses are involved because manufacturing variations become proportionately more significant. The locally-reduced cross section portions described in this document are formed by pairs of circular holes. The shape of the locally-reduced cross section portions undesirably concentrates the plastic strain at the narrowest portion. This concentration of plastic strain without any provision for controlling the level of plastic strain makes the stent highly vulnerable to failure.


In view of the drawbacks of the prior art stents, it would be advantageous to be able to expand a stent with an expansion force at a low level independent of choice of stent materials, material thickness, or strut dimensions.


It would further be advantageous to have a tissue-supporting device that permits a choice of material thickness that could be viewed easily on conventional fluoroscopic equipment for any material.


It would also be advantageous to have a tissue-supporting device that is inherently stable during expansion, thus eliminating buckling and twisting of structural features during stent deployment.


It would also be desirable to control strain to a desired level which takes advantage of work hardening without approaching a level of plastic strain at which failure may occur.


In addition, it would be advantageous to have a tissue-supporting device with minimal elastic recovery, or “recoil” of the device after expansion.


It would be advantageous to have a tissue supporting device that can be securely crimped to the delivery catheter without requiring special tools, techniques, or ancillary clamping features.


It would further be advantageous to have a tissue-supporting device that has improved resistance to compressive forces (improved crush strength) after expansion.


It would also be advantageous to have a tissue-supporting device that achieves all the above improvements with minimal foreshortening of the overall stent length during expansion.


SUMMARY OF THE INVENTION

The present invention addresses several important problems in expandable medical device design including: high expansion force requirements; lack of radio-opacity in thin-walled stents; buckling and twisting of stent features during expansion; poor crimping properties; and excessive elastic recovery (“recoil”) after implantation. The invention also provides benefits of improved resistance to compressive forces after expansion, control of the level of plastic strain, and low axial shortening during expansion. Some embodiments of the invention also provide improved uniformity of expansion by limiting a maximum geometric deflection between struts. The invention may also incorporate sites for the inclusion of beneficial agent delivery.


The invention involves the incorporation of stress/strain concentration features or “ductile hinges” at selected points in the body of an expandable cylindrical medical device. When expansion forces are applied to the device as a whole, these ductile hinges concentrate expansion stresses and strains in small, well-defined areas while limiting strut deflection and plastic strain to specified levels.


In accordance with one aspect of the present invention, an expandable medical device includes a plurality of cylindrical tubes each formed of a plurality of adjacent struts interconnected at alternating ends. The plurality of cylindrical tubes are expandable from a first diameter to a second diameter at which the adjacent struts form substantially V-shapes. The plurality of cylindrical tubes are arranged with the interconnected ends of the struts aligned facing each other in adjacent cylindrical tubes. A plurality of S-shaped bridging elements are connected between the interconnected ends of the struts in adjacent cylindrical tubes. The bridging elements are connected entirely above a midline of the V-shapes on one cylindrical tube and entirely below the midline of the V-shapes on an adjacent cylindrical tube.


In accordance with a further aspect of the invention, an expandable medical device includes a plurality of cylindrical tubes each formed of a plurality of adjacent struts interconnected at alternating ends. The plurality of cylindrical tubes are expandable from a first diameter at which the adjacent struts are substantially parallel to one another to a second diameter at which the adjacent struts form substantially V-shapes. The plurality of cylindrical tubes are arranged such that interconnected ends of the struts are aligned facing each other in adjacent cylindrical tubes. A plurality of S-shaped bridging elements are connected between the interconnected ends of the struts in adjacent cylindrical tubes. Each of the bridging elements cross a midline of the V-shapes three times and are connected entirely above the midline of the V-shapes on one cylindrical tube and entirely below the midline of the V-shapes on an adjacent cylindrical tube.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:



FIG. 1 is an isometric view of a prior art tissue-supporting device;



FIG. 2 is an isometric view of a tissue-supporting device in accordance with one embodiment of the invention;



FIGS. 3
a-d are perspective views of ductile hinges according to several variations of the invention;



FIG. 3
e is a side view of another embodiment of a ductile hinge;



FIGS. 4
a and 4b are an isometric view and an enlarged side view of a tissue-supporting device in accordance with an alternative embodiment of the invention;



FIGS. 5
a-c are perspective, side, and cross-sectional views of an idealized ductile hinge for purposes of analysis;



FIG. 5
d is a stress/strain curve for the idealized ductile hinge;



FIGS. 6 is a perspective view of a simple beam for purposes of calculation;



FIG. 7 is a moment verses curvature graph for a rectangular beam;



FIG. 8 is an enlarged side view of a bent ductile hinge;



FIGS. 9
a and 9b are enlarged side views of ductile hinges in initial and expanded positions with shortened struts to illustrate axial contraction relationships; and



FIG. 10 is a side view of a portion of an alternative embodiment of a tissue supporting device having a high-crush-strength and low-recoil.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS


FIG. 2 shows one embodiment of an expandable tissue supporting device 20 in accordance with the present invention. The tissue supporting device 20 includes a series of axial slots 22 formed in a cylindrical tube 24. Each axial slot 22 is displaced axially from the slots in adjacent rows of slots by approximately half the slot length resulting in a staggered slot arrangement. The offset between adjacent rows of slots results in alternate rows of slots which extend to the ends of the cylindrical tube 24. At each interior end of each of the axial slots 22 a circumferential slot 26 is formed. The material between the slots 22 forms a network of axial struts 28 extending substantially parallel to an axis of the tube 24. The axial struts 28 are joined by short circumferential links 30. The circumferential links 30 are positioned at both the interior of the cylindrical tube and at the ends of the cylindrical tube. The cross section (and rectangular moment of inertia) of each of the struts 28 is not constant along the length of the strut. Rather, the strut cross section changes abruptly at both ends of each strut 28 at the location of the circumferential slots 26. The struts 28 are thus not prismatic. Each individual strut 28 is linked to the rest of the structure through a pair of reduced sections 32, one at each end, which act as stress/strain concentration features. The reduced sections 32 of the struts function as hinges in the cylindrical structure. Since the stress/strain concentration features 32 are designed to operate into the plastic deformation range of generally ductile materials, they are referred to as ductile hinges. Such features are also commonly referred to as “Notch Hinges” or “Notch Springs” in ultra-precision mechanism design, where they are used exclusively in the elastic range.


With reference to the drawings and the discussion, the width of any feature is defined as its dimension in the circumferential direction of the cylinder. The length of any feature is defined as its dimension in the axial direction of the cylinder. The thickness of any feature is defined as the wall thickness of the cylinder.


The presence of the ductile hinges 32 allows all of the remaining features in the tissue supporting device to be increased in width or the circumferentially oriented component of their respective rectangular moments of inertia—thus greatly increasing the strength and rigidity of these features. The net result is that elastic, and then plastic deformation commence and propagate in the ductile hinges 32 before other structural elements of the device undergo any significant elastic deformation. The force required to expand the tissue supporting device 20 becomes a function of the geometry of the ductile hinges 32, rather than the device structure as a whole, and arbitrarily small expansion forces can be specified by changing hinge geometry for virtually any material wall thickness. In particular, wall thicknesses great enough to be visible on a fluoroscope can be chosen for any material of interest.


In order to get minimum recoil, the ductile hinges 32 should be designed to operate well into the plastic range of the material, and relatively high local strain-curvatures are developed. When these conditions apply, elastic curvature is a very small fraction of plastic or total curvature, and thus when expansion forces are relaxed, the percent change in hinge curvature is very small. When incorporated into a strut network designed to take maximum advantage of this effect, the elastic springback, or “recoil,” of the overall stent structure is minimized.


In the embodiment of FIG. 2, it is desirable to increase the width of the individual struts 28 between the ductile hinges 32 to the maximum width that is geometrically possible for a given diameter and a given number of struts arrayed around that diameter. The only geometric limitation on strut width is the minimum practical width of the slots 22 which is about 0.002 inches (0.0508 mm) for laser machining. Lateral stiffness of the struts 28 increases as the cube of strut width, so that relatively small increases in strut width significantly increase strut stiffness. The net result of inserting ductile hinges 32 and increasing strut width is that the struts 28 no longer act as flexible leaf springs, but act as essentially rigid beams between the ductile hinges. All radial expansion or compression of the cylindrical tissue supporting device 20 is accommodated by mechanical strain in the hinge features 32, and yield in the hinge commences at very small overall radial expansion or compression.


Yield in ductile hinges at very low gross radial deflections also provides the superior crimping properties displayed by the ductile hinge-based designs. When a tissue supporting device is crimped onto a folded catheter balloon, very little radial compression of the device is possible since the initial fit between balloon and device is already snug. Most stents simply rebound elastically after such compression, resulting in very low clamping forces and the attendant tendency for the stent to slip on the balloon. Ductile hinges, however, sustain significant plastic deformation even at the low deflections occurring during crimping onto the balloon, and therefore a device employing ductile hinges displays much higher clamping forces. The ductile hinge designs according to the present invention may be securely crimped onto a balloon of a delivery catheter by hand or by machine without the need for auxiliary retaining devices commonly used to hold known stents in place.


The geometric details of the stress/strain concentration features or ductile hinges 32 can be varied greatly to tailor the exact mechanical expansion properties to those required in a specific application. The most obvious and straightforward ductile hinges are formed by slots or notches with rounded roots, as in FIGS. 3a and 3c. Since the laser beams often used to fabricate these features are themselves round, slots or notches with circular roots are also among the easiest to fabricate.



FIG. 3
a shows a ductile hinge 36 formed by a pair of opposed circular grooves 38, 40. According to this embodiment the circumferential slot 26 has semicircular ends 38 having a radius of curvature. Outer semicircular grooves 40 oppose the semicircular ends 38 and also have a radius of curvature which is the same as that of the grooves 38. FIG. 3c shows another ductile hinge 54 formed by a parabolic groove 56.


Generally, the ductile hinges 36 of the embodiment of FIG. 3a formed between pairs of concave curves 38, 40 have a minimum width along a line connecting their respective centers of curvature. When the struts connected by the ductile hinge are moved apart or together, plastic deformation is highly concentrated in a region immediately adjacent to the plane that bisects the hinge at this narrow point.


For smaller deflection, this very high strain concentration at the bisecting plane is acceptable, and in some cases, useful. For stent crimping purposes, for example, it is desirable to generate relatively large plastic deformations at very small deflection angles.


As a practical matter, however, strut deflection angles for device expansion are often in the 25° to 45° range. At these angles, strain at the root or bisecting plane of concave ductile hinge features can easily exceed the 50 to 60% elongation-to-failure of 316L stainless steel, one of the most ductile stent materials. Deflection limiting features which will be described further below limit the geometric deflection of struts, but these features do not in themselves affect the propagation pattern of plastic deformation in a given ductile hinge design. For concave ductile hinges at large bend angles, very high strain concentrations remain. Scanning electron micrographs have confirmed this analysis.


In many engineering applications, it is desirable to limit the amount of strain, or “cold-work,” in a material to a specified level in order to optimize material properties and to assure safe operation. For example, in medical applications it is desirable to limit the amount of cold-work in 316L stainless steel to about 30%. At this level, the strength of the material is increased, while the material strain is still well below the failure range. Ideally, therefore, a safe and effective ductile hinge should not simply limit gross deflection, but reliably limit material strain to a specified level.



FIG. 3
b shows a simple ductile hinge design that allows material strain to be limited to some specified level. The ductile hinge of FIG. 3b is formed by a rectangular circumferential groove 46 with filleted corners 48 on one side of a strut, the opposite side 50 of the strut remaining straight. The ductile hinges 44 are substantially rectangular sections between the ends of the groove 46 and the side walls 50.


One of the key concepts in FIG. 3b is that the ductile hinge 44 has a constant or substantially constant width along at least a portion of its total length. In this configuration, there is no local minimum width along the ductile hinge axis, as there is with pairs of concave roots. There is therefore no point concentration of stresses and strains along the length of the ductile hinge beam during stent expansion. In particular, maximum tensile and compressive strains will be distributed evenly along the upper and lower surfaces of the hinge 44 during stent expansion. With the gross bend angle limited by mechanical stops, which are described below in detail, the maximum material strain (at the hinge surfaces) can therefore be reliably limited by adjusting the initial length of the ductile hinge over which the total elongation is distributed.



FIG. 3
d shows a ductile hinge 60 in a cylindrical wire 62 for incorporating into a wire-form tissue-supporting device. The ductile hinge 60 is formed by a reduced diameter portion of the wire 62. Again, it is important that the ductile hinge have a substantially constant width over a portion of its length in order to provide strain control. Preferably, the ductile hinge is prismatic over a portion of its length. Maximum material strain can be varied by adjusting the hinge length. The ductile hinges of the present invention have a constant or substantially constant width over at least ⅓ of the ductile hinge length, and preferably over at least ½ of the ductile hinge length.



FIG. 3
e shows an asymmetric ductile hinge 64 that produces different strain versus deflection-angle functions in expansion and compression. Each of the ductile hinges 64 is formed between a convex surface 68 and a concave surface 69. The ductile hinge 64 according to a preferred embodiment essentially takes the form of a small, prismatic curved beam having a substantially constant cross section. However, a thickness of the curved ductile hinge 64 may vary somewhat as long as the ductile hinge width remains constant along a portion of the hinge length. The width of the curved beam is measured along the radius of curvature of the beam. This small curved beam is oriented such that the small concave surface 69 is placed in tension in the device crimping direction, while the larger convex surface 68 of the ductile hinges is placed in tension in the device expansion direction. Again, there is no local minimum width of the ductile hinge 64 along the (curved) ductile hinge axis, and no concentration of material strain. During device expansion tensile strain will be distributed along the convex surface 68 of the hinge 64 and maximum expansion will be limited by the angle of the walls of the concave notch 69 which provide a geometric deflection limiting feature. Maximum tensile strain can therefore be reliably limited by adjusting the initial length of the convex arc shaped ductile hinge 64 over which the total elongation is distributed.


The ductile hinges illustrated in FIGS. 3a-e are examples of different structures that will function as a stress/strain concentrator. Many other stress/strain concentrator configurations may also be used as the ductile hinges in the present invention. The ductile hinges according to the present invention generally include an abrupt change in width of a strut that functions to concentrate stresses and strains in the narrower section of the strut. These ductile hinges also generally include features to limit mechanical deflection of attached struts and features to control material strain during large strut deflections. Although the ductile hinges have been illustrated in FIG. 2 as positioned at the ends of each of the axial slots 22, they may also be positioned at other locations in other designs without departing from the present invention.


An alternative embodiment of a tissue supporting device 80 is illustrated in FIG. 4a and in the enlarged side view of FIG. 4b. The tissue supporting device 80 includes a plurality of cylindrical tubes 82 connected by S-shaped bridging elements 84. The bridging elements 84 allow the tissue supporting device to bend axially when passing through the tortuous path of the vasculature to the deployment site and allow the device to bend when necessary to match the curvature of a lumen to be supported. The S-shaped bridging elements 84 provide improved axial flexibility over prior art devices due to the thickness of the elements in the radial direction which allows the width of the elements to be relatively small without sacrificing radial strength. For example, the width of the bridging elements 84 may be about 0.0012-0.0013 inches (0.0305-0.0330 mm). Each of the cylindrical tubes 82 has a plurality of axial slots 86 extending from an end surface of the cylindrical tube toward an opposite end surface. A plurality of axial struts 88 having ductile hinges 90 are formed between the axial slots 86. The ductile hinges 90 are formed by circumferential slots 92 formed at the interior ends of the axial slots 86 and opposed notches 94.


The notches 94 each have two opposed angled walls 96 which function as a stop to limit geometric deflection of the ductile hinge, and thus limit maximum device expansion. As the cylindrical tubes 82 are expanded and bending occurs at the ductile hinges 90, the angled side walls 96 of the notches 94 move toward each other. Once the opposite side walls 96 of a notch come into contact with each other, they resist further expansion of the particular ductile hinge causing further expansion to occur at other sections of the tissue supporting device. This geometric deflection limiting feature is particularly useful where uneven expansion is caused by either variations in the tissue supporting device 80 due to manufacturing tolerances or uneven balloon expansion.


The tissue supporting device 20, 80 according to the present invention may be formed of any ductile material, such as steel, gold, silver, tantalum, titanium, Nitinol, other shape memory alloys, other metals, or even some plastics. One preferred method for making the tissue supporting device 20, 80 involves forming a cylindrical tube and then laser cutting the slots 22, 26, 86, 92 and notches 94 into the tube. Alternatively, the tissue supporting device may be formed by electromachining, chemical etching followed by rolling and welding, or any other known method.


The design and analysis of stress/strain concentration for ductile hinges, and stress/strain concentration features in general, is complex. For example, the stress concentration factor for the simplified ductile hinge geometry of FIG. 3a can be calculated and is given by the following expression where D is the width of the struts 28, h is the height of the circular grooves 38, 40, and r is the radius of curvature of the grooves. For purposes of this example the ratio of h/r is taken to be 4. However, other ratios of h/r can also be implemented successfully.






K
=

4.935
-

7.586


(


2

h

D

)


+

0.515



(


2

h

D

)

2


+

0.432



(


2

h

D

)

3







The stress concentration factors are generally useful only in the linear elastic range. Stress concentration patterns for a number of other geometries can be determined through photoelastic measurements and other experimental methods. Stent designs based on the use of stress/strain concentration features, or ductile hinges, generally involve more complex hinge geometries and operate in the non-linear elastic and plastic deformation regimes.


The general nature of the relationship among applied forces, material properties, and ductile hinge geometry can be more easily understood through analysis of an idealized hinge 66 as shown in FIGS. 5a-5c. The hinge 66 is a simple beam of rectangular cross section having a width h, length L and thickness b. The idealized hinge 66 has elastic-ideally-plastic material properties which are characterized by the ideal stress/strain curve of FIG. 5d. It can be shown that the “plastic” or “ultimate bending moment” for such a beam is given by the expression:








M
p



M
ult


=


δ
yp




bh
2

4







Where b corresponds to the cylindrical tube wall thickness, h is the circumferential width of the ductile hinge, and δyp is the yield stress of the hinge material. Assuming only that expansion pressure is proportional to the plastic moment, it can be seen that the required expansion pressure to expand the tissue supporting device increases linearly with wall thickness b and as the square of ductile hinge width h. It is thus possible to compensate for relatively large changes in wall thickness b with relatively small changes in hinge width h. While the above idealized case is only approximate, empirical measurements of expansion forces for different hinge widths in several different ductile hinge geometries have confirmed the general form of this relationship. Accordingly, for different ductile hinge geometries it is possible to increase the thickness of the tissue supporting device to achieve radiopacity while compensating for the increased thickness with a much smaller decrease in hinge width.


Ideally, the stent wall thickness b should be as thin as possible while still providing good visibility on a fluoroscope. For most stent materials, including stainless steel, this would suggest a thickness of about 0.005-0.007 inches (0.127-0.178 mm) or greater. The inclusion of ductile hinges in a stent design can lower expansion forces/pressures to very low levels for any material thickness of interest. Thus ductile hinges allow the construction of optimal wall thickness tissue supporting devices at expansion force levels significantly lower than current non-visible designs.


The expansion forces required to expand the tissue supporting device 20 according to the present invention from an initial condition illustrated in FIG. 2 to an expanded condition is between 1 and 5 atmospheres, preferably between 2 and 3 atmospheres. The expansion may be performed in a known manner, such as by inflation of a balloon or by a mandrel. The tissue supporting device 20 in the expanded condition has a diameter which is preferably up to three times the diameter of the device in the initial unexpanded condition.


Many tissue supporting devices fashioned from cylindrical tubes comprise networks of long, narrow, prismatic beams of essentially rectangular cross section as shown in FIG. 6. These beams which make up the known tissue supporting devices may be straight or curved, depending on the particular design. Known expandable tissue supporting devices have a typical wall thickness b of 0.0025 inches (0.0635 mm), and a typical strut width h of 0.005 to 0.006 inches (0.127 -0.1524 mm). The ratio of b:h for most known designs is 1:2 or lower. As b decreases and as the beam length L increases, the beam is increasingly likely to respond to an applied bending moment M by buckling, and many designs of the prior art have displayed this behavior. This can be seen in the following expression for the “critical buckling moment” for the beam of FIG. 6.







M
crit

=



π






b
3


h







EG
(

1
-

0.63






b
/
h






)


6

L








    • Where: E=Modulus of Elasticity
      • G=Shear Modulus





By contrast, in a ductile hinge based design according to the present invention, only the hinge itself deforms during expansion. The typical ductile hinge 32 is not a long narrow beam as are the struts in the known stents. Wall thickness of the present invention may be increased to 0.005 inches (0.127 mm) or greater, while hinge width is typically 0.002-0.003 inches (0.0508-0.0762 mm), preferably 0.0025 inches (0.0635 mm) or less. Typical hinge length, at 0.002 to 0.005 inches (0.0508-0.0127 mm), is more than an order of magnitude less than typical strut length. Thus, the ratio of b:h in a typical ductile hinge 32 is 2:1 or greater. This is an inherently stable ratio, meaning that the plastic moment for such a ductile hinge beam is much lower than the critical buckling moment Mcrit, and the ductile hinge beam deforms through normal strain-curvature. Ductile hinges 32 are thus not vulnerable to buckling when subjected to bending moments during expansion of the tissue supporting device 20.


To provide optimal recoil and crush-strength properties, it is desirable to design the ductile hinges so that relatively large strains, and thus large curvatures, are imparted to the hinge during expansion of the tissue supporting device. Curvature is defined as the reciprocal of the radius of curvature of the neutral axis of a beam in pure bending. A larger curvature during expansion results in the elastic curvature of the hinge being a small fraction of the total hinge curvature. Thus, the gross elastic recoil of the tissue supporting device is a small fraction of the total change in circumference. It is generally possible to do this because common stent materials, such as 316L Stainless Steel have very large elongations-to-failure (i.e., they are very ductile).


It is not practical to derive exact expressions for residual curvatures for complex hinge geometries and real materials (i.e., materials with non-idealized stress/strain curves). The general nature of residual curvatures and recoil of a ductile hinge may be understood by examining the moment-curvature relationship for the elastic-ideally-plastic rectangular hinge 66 shown in FIGS. 5a-c. It may be shown that the relationship between the applied moment and the resulting beam curvature is:






M
=


M
p

[


1
-


1
3



(


y
o


h
/
2


]



=


3
/
2




M
yp

[

1
-


1
3




(


K
yp

K

)

2



]








This function is plotted in FIG. 7. It may be seen in this plot that the applied moment M asymptotically approaches a limiting value Mp, called the plastic or ultimate moment. Beyond 11/12 Mp large plastic deformations occur with little additional increase in applied moment. When the applied moment is removed, the beam rebounds elastically along a line such as a-b. Thus, the elastic portion of the total curvature approaches a limit of 3/2 the curvature at the yield point. These relations may be expressed as follows:







M
p

=




3
2



M
yp




K
rebound


=


3
2



K
yp







Imparting additional curvature in the plastic zone cannot further increase the elastic curvature, but will decrease the ratio of elastic to plastic curvature. Thus, additional curvature or larger expansion of the tissue supporting device will reduce the percentage recoil of the overall stent structure.


As shown in FIG. 8, when a rigid strut 28 is linked to the ductile hinge 66 described above, the strut 28 forms an angle with the horizontal that is a function of hinge curvature. A change in hinge curvature results in a corresponding change in this angle θ. The angular elastic rebound of the hinge is the change in angle Δθ that results from the rebound in elastic curvature described above, and thus angular rebound also approaches a limiting value as plastic deformation proceeds. The following expression gives the limiting value of angular elastic rebound for the idealized hinge of FIG. 8.







θ
rebound

=

3






ε
yp



L
h







Where strain at the yield point is an independent material property (yield stress divided by elastic modulus); L is the length of the ductile hinge; and h is the width of the hinge. For non-idealized ductile hinges made of real materials, the constant 3 in the above expression is replaced by a slowly rising function of total strain, but the effect of geometry would remain the same. Specifically, the elastic rebound angle of a ductile hinge decreases as the hinge width h increases, and increases as the hinge length L increases. To minimize recoil, therefore, hinge width h should be increased and length L should be decreased.


Ductile hinge width h will generally be determined by expansion force criteria, so it is important to reduce hinge length to a practical minimum in order to minimize elastic rebound. Empirical data on recoil for ductile hinges of different lengths show significantly lower recoil for shorter hinge lengths, in good agreement with the above analysis.


The ductile hinges 32 of the tissue supporting device 20 provide a second important advantage in minimizing device recoil. The embodiment of FIG. 2 shows a network of struts joined together through ductile hinges to form a cylinder. In this design, the struts 28 are initially parallel to an axis of the device. As the device is expanded, curvature is imparted to the hinges 32, and the struts 28 assume an angle with respect to their original orientation, as shown in FIG. 8. The total circumferential expansion of the tissue supporting device structure is a function of hinge curvature (strut angle) and strut length. Moreover, the incremental contribution to stent expansion (or recoil) for an individual strut depends on the instantaneous strut angle. Specifically, for an incremental change in strut angle Δθ, the incremental change in circumference ΔC will depend on the strut length R and the cosine of the strut angle θ.

ΔC=RΔθ cos θ


Since elastic rebound of hinge curvature is nearly constant at any gross curvature, the net contribution to circumferential recoil ΔC is lower at higher strut angles θ. The final device circumference is usually specified as some fixed value, so decreasing overall strut length can increase the final strut angle θ. Total stent recoil can thus be minimized with ductile hinges by using shorter struts and higher hinge curvatures when expanded.


Empirical measurements have shown that tissue supporting device designs based on ductile hinges, such as the embodiment of FIG. 2, display superior resistance to compressive forces once expanded despite their very low expansion force. This asymmetry between compressive and expansion forces may be due to a combination of factors including the geometry of the ductile hinge, the increased wall thickness, and increased work hardening due to higher strain levels.


According to one example of the tissue supporting device of the invention, the device can be expanded by application of an internal pressure of about 2 atmospheres or less, and once expanded to a diameter between 2 and 3 times the initial diameter can withstand a compressive force of about 16 to 20 gm/mm or greater. Examples of typical compression force values for prior art devices are 3.8 to 4.0 gm/mm.


While both recoil and crush strength properties of tissue supporting devices can be improved by use of ductile hinges with large curvatures in the expanded configuration, care must be taken not to exceed an acceptable maximum strain level for the material being used. For the ductile hinge 44 of FIG. 3b, for example, it may be shown that the maximum material strain for a given bend angle is given by the expression:







ɛ
max

=


h
L



θ
2






Where εmax is maximum strain, h is ductile hinge width, L is ductile hinge length and θ is bend angle in radians. When strain, hinge width and bend angle are determined through other criteria, this expression can be evaluated to determine the correct ductile hinge length L.


For example, suppose the ductile hinge 44 of FIG. 3b was to be fabricated of 316L stainless steel with a maximum strain of 30%; ductile hinge width h is set at 0.0025 inch (0.0635 mm) by expansion force criteria; and the bend angle θ is mechanically limited to 0.5 radians (≅30%) at full stent expansion. Solving the above expression for L gives the required ductile hinge length of at least about 0.0033 inches (0.0838 mm).


Similar expressions may be developed to determine required lengths for more complicated ductile hinge geometries, such as shown in FIG. 3e. Typical values for the prismatic portions of these curved ductile hinges range from about 0.002 to about 0.0035 inches (0.051-0.089 mm) in hinge width and about 0.002 to about 0.006 inches (0.051-0.152 mm) in hinge length. The tissue supporting device design of FIGS. 4a and 4b include a stop which limits the maximum geometric deflection at the ductile hinges by the design of the angled walls 96 of the notches 94.


In many designs of the prior art, circumferential expansion was accompanied by a significant contraction of the axial length of the stent which may be up to 15 % of the initial device length. Excessive axial contraction can cause a number of problems in device deployment and performance including difficulty in proper placement and tissue damage. Designs based on ductile hinges 32 can minimize the axial contraction, or foreshortening, of a tissue supporting device during expansion as follows.



FIGS. 9
a and 9b illustrate an exaggerated ductile hinge 32 and shortened struts 28 in initial and expanded conditions. Each strut 28 is attached to two ductile hinges 32 at opposite ends. Each ductile hinge 32 has an instant center of rotation C1, C2 that is an effective pivot point for the attached strut 28. Initially, during expansion the pivot point C1 is displaced vertically by a distance d until C1 is positioned even with C2 as shown in FIG. 9b. When the array is expanded vertically, the axial struts 28 move in a circular arc with respect to the pivot points, as shown in FIG. 9b. It can be seen that the horizontal distance e between pivot points C1 and C2 actually increases initially, reaching a maximum emax when the two points are on the same horizontal axis as shown in FIG. 9b. As the vertical expansion continues, the device compresses axially back to its original length. Only when vertical expansion of the array continues beyond the point where the horizontal distance e between C1 and C2 is the same as the original horizontal distance e does the overall length of the array actually begin to contract. For the stent shown in FIG. 2, for example, approximately ⅓ of the total circumferential expansion has been accomplished by the time the configuration of FIG. 9b is reached, and the stent exhibits very low axial contraction.


This ability to control axial contraction based on hinge and strut design provides great design flexibility when using ductile hinges. For example, a stent could be designed with zero axial contraction.


An alternative embodiment that illustrates the trade off between crush strength and axial contraction is shown in FIG. 10. FIG. 10 shows a portion of a tissue supporting device 70 having an array of struts 72 and ductile hinges 74 in the unexpanded state. The struts 72 are positioned initially at an angle θ1 with respect to a longitudinal axis X of the device. As the device is expanded radially from the unexpanded state illustrated in FIG. 10, the angle θ1 increases. In this case the device contracts axially from the onset of vertical expansion throughout the expansion. Once the device has been completely expanded the final angle θ1 made by the strut 72 with the horizontal will be much greater than the angle θ in the device of FIG. 8a and 8b. As shown previously, a higher final strut angle θ1, can significantly increase crush strength and decrease circumferential recoil of the stent structure. However, there is a trade off between increased crush strength and increase in axial contraction.


According to one example of the present invention, the struts 72 are positioned initially at an angle of about 0° to 45° with respect to a longitudinal axis of the device. As the device is expanded radially from the unexpanded state illustrated in FIG. 10, the strut angle increases to about 20° to 80°.


According to one alternative embodiment of the present invention, the expandable tissue supporting device can also be used as a delivery device for certain beneficial agents including drugs, chemotherapy, or other agents. Due to the structure of the tissue supporting device incorporating ductile hinges, the widths of the struts can be substantially larger than the struts of the prior art devices. The struts due to their large size can be used for beneficial agent delivery by providing beneficial agent on the struts or within the struts. Examples of beneficial agent delivery mechanisms include coatings on the struts, such as polymer coatings containing beneficial agents, laser drilled holes in the struts containing beneficial agent, and the like.


While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.

Claims
  • 1. A cylindrical expandable stent comprising: a plurality of cylindrical tubes each formed of a plurality of connected adjacent struts, the plurality of cylindrical tubes expandable from a first diameter to a second diameter; wherein when in the second diameter, at least some of the adjacent struts form a substantially V-shape with respect to each other, said V-shape having a midline parallel to the longitudinal axis of the stent, said adjacent struts interconnected at alternating ends to define an apex for each V-shape;a plurality of “S”-shaped bridging elements connected between the adjacent cylindrical tubes, one end of each said “S”-shaped element having a pair of ends forming an end of said “S”-shape, said “S”-shaped element connected to one V-shape on a first cylindrical tube and the second end of said “S”-shaped element connected to an opposing V-shape on a second cylindrical tube, wherein each of the bridging elements are connected to a cylindrical tube entirely above a midline of each of the V-shapes on one cylindrical tube and entirely below the midline of each of the V-shapes on an adjacent cylindrical tube; andwherein each of the bridging elements crosses a midline of a V-shape three times.
  • 2. The device of claim 1, wherein the S-shaped bridging elements have an undulating shape extending through greater than 360 degrees.
  • 3. The device of claim 1, wherein the bridging elements are located at a diagonal orientation such that a line extending through the connecting points on either end of each of the bridging elements is located at an angle with respect to a longitudinal axis of the cylindrical tubes.
  • 4. The device of claim 3, wherein all the bridging elements interconnecting two adjacent ones of the cylindrical tubes are located at the same diagonal orientation.
  • 5. The device of claim 1, wherein the bridging elements have a width less than a width of the struts.
  • 6. The device of claim 1, wherein the plurality of adjacent struts are interconnected by ductile hinges and circumferential links.
  • 7. The device of claim 1, wherein the bridging elements allow the device to bend axially.
  • 8. The device of claim 1, wherein the plurality of cylindrical tubes are arranged with V-shapes in one tube substantially at 180 degrees out of phase with respect to the V-shapes of the adjacent cylindrical tubes.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 10/231,007, filed Aug. 30, 2002, now abandoned which is a continuation of U.S. patent application Ser. No. 09/649,217, filed Aug. 28, 2000, now issued as U.S. Pat. No. 6,562,065, which is a continuation of U.S. patent application Ser. No. 09/183,555, filed Oct. 29, 1998, now issued as U.S. Pat. No. 6,241,762 which claims priority to U.S. Provisional Patent Application Ser. No. 60/079,881, filed Mar. 30, 1998, the entire contents of which are incorporated herein by reference.

US Referenced Citations (472)
Number Name Date Kind
3657744 Ersek Apr 1972 A
4300244 Bukros Nov 1981 A
4531936 Gordon Jul 1985 A
4542025 Tice et al. Sep 1985 A
4580568 Gianturco Apr 1986 A
4650466 Luther Mar 1987 A
4733665 Palmaz Mar 1988 A
4739762 Palmaz Apr 1988 A
4776337 Palmaz Oct 1988 A
4800882 Gianturco Jan 1989 A
4824436 Wollinsky Apr 1989 A
4834755 Silvestrini et al. May 1989 A
4889119 Jamiolkowski et al. Dec 1989 A
4916193 Tang et al. Apr 1990 A
4955878 See et al. Sep 1990 A
4957508 Kaneko et al. Sep 1990 A
4960790 Steela et al. Oct 1990 A
4969458 Wiktor Nov 1990 A
4989601 Marchosky et al. Feb 1991 A
4990155 Wilkoff et al. Feb 1991 A
4994071 MacGregor Feb 1991 A
5017381 Maruyama et al. May 1991 A
5019090 Pinchuk May 1991 A
5049132 Shaffer et al. Sep 1991 A
5053048 Pinchuk Oct 1991 A
5059166 Fischell et al. Oct 1991 A
5059178 Ya et al. Oct 1991 A
5059211 Stack et al. Oct 1991 A
5078726 Kreamer Jan 1992 A
5085629 Goldberg et al. Feb 1992 A
5092841 Spears Mar 1992 A
5102417 Palmaz Apr 1992 A
5104404 Wolff Apr 1992 A
5139480 Hickle et al. Aug 1992 A
5157049 Haugwitz et al. Oct 1992 A
5160341 Brenneman et al. Nov 1992 A
5171217 March et al. Dec 1992 A
5171262 MacGregor Dec 1992 A
5176617 Fischell et al. Jan 1993 A
5195984 Schatz Mar 1993 A
5197978 Hess Mar 1993 A
5213580 Slepian et al. May 1993 A
5223092 Grinnell et al. Jun 1993 A
5234456 Silvestrini Aug 1993 A
5242399 Lau et al. Sep 1993 A
5282823 Schwartz et al. Feb 1994 A
5283257 Gregory et al. Feb 1994 A
5286254 Shapland et al. Feb 1994 A
5288711 Mitchell et al. Feb 1994 A
5290271 Jernberg Mar 1994 A
5292512 Schaefer et al. Mar 1994 A
5304121 Sahatjian Apr 1994 A
5314688 Kauffman et al. May 1994 A
5342348 Kaplan Aug 1994 A
5342621 Eury Aug 1994 A
5344426 Lau et al. Sep 1994 A
5380299 Fearnot et al. Jan 1995 A
5383892 Cardon et al. Jan 1995 A
5383928 Scott et al. Jan 1995 A
5403858 Bastard et al. Apr 1995 A
5407683 Shively Apr 1995 A
5415869 Straubinger et al. May 1995 A
5419760 Narciso May 1995 A
5439446 Barry Aug 1995 A
5439686 Desai et al. Aug 1995 A
5441515 Khosravi et al. Aug 1995 A
5441745 Presant et al. Aug 1995 A
5443458 Eury Aug 1995 A
5443496 Schwartz et al. Aug 1995 A
5443497 Venbrx Aug 1995 A
5443500 Sigwart Aug 1995 A
5447724 Helmus et al. Sep 1995 A
5449373 Pinchasik et al. Sep 1995 A
5449382 Dayton Sep 1995 A
5449513 Yokoyama et al. Sep 1995 A
5457113 Cullinan et al. Oct 1995 A
5460817 Langley et al. Oct 1995 A
5462866 Wang Oct 1995 A
5464450 Buscemi et al. Nov 1995 A
5464650 Berg et al. Nov 1995 A
5472985 Grainger et al. Dec 1995 A
5473055 Mongelli et al. Dec 1995 A
5496365 Sgro Mar 1996 A
5499373 Richards et al. Mar 1996 A
5500013 Buscemi et al. Mar 1996 A
5510077 Dinh et al. Apr 1996 A
5512055 Domb et al. Apr 1996 A
5516781 Morris et al. May 1996 A
5519954 Garrett May 1996 A
5523092 Hanson et al. Jun 1996 A
5527344 Arzbaecher et al. Jun 1996 A
5534287 Lukic Jul 1996 A
5545208 Wolff et al. Aug 1996 A
5545210 Hess et al. Aug 1996 A
5545569 Grainger et al. Aug 1996 A
5551954 Buscemi et al. Sep 1996 A
5554182 Dinh et al. Sep 1996 A
5556413 Lam Sep 1996 A
5562922 Lambert Oct 1996 A
5563146 Morris et al. Oct 1996 A
5571089 Crocker Nov 1996 A
5571166 Dinh et al. Nov 1996 A
5575571 Takebayashi et al. Nov 1996 A
5578075 Dayton Nov 1996 A
5591224 Schwartz et al. Jan 1997 A
5591227 Dinh et al. Jan 1997 A
5593434 Williams Jan 1997 A
5595722 Grainger et al. Jan 1997 A
5599352 Dinh et al. Feb 1997 A
5599722 Sugisaka et al. Feb 1997 A
5599844 Grainger et al. Feb 1997 A
5605696 Eury et al. Feb 1997 A
5607442 Fischell et al. Mar 1997 A
5607463 Schwartz et al. Mar 1997 A
5607475 Cahalan et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5609629 Fearnot et al. Mar 1997 A
5616608 Kinsella et al. Apr 1997 A
5617878 Taheri Apr 1997 A
5618299 Khosravi et al. Apr 1997 A
5624411 Tuch Apr 1997 A
5628785 Schwartz et al. May 1997 A
5628787 Mayer May 1997 A
5629077 Turnlund et al. May 1997 A
5632840 Campbell May 1997 A
5637113 Tartaglia et al. Jun 1997 A
5643312 Fischell et al. Jul 1997 A
5643314 Carpenter et al. Jul 1997 A
5646160 Morris et al. Jul 1997 A
5649977 Campbell Jul 1997 A
5651174 Schwartz et al. Jul 1997 A
5660873 Nikolaychik et al. Aug 1997 A
5665591 Sonenshein et al. Sep 1997 A
5667764 Kopia et al. Sep 1997 A
5670161 Healy et al. Sep 1997 A
5670659 Alas et al. Sep 1997 A
5674241 Bley et al. Oct 1997 A
5674242 Phan et al. Oct 1997 A
5674278 Boneau Oct 1997 A
5679400 Tuch Oct 1997 A
5693085 Buirge et al. Dec 1997 A
5695516 Fischell et al. Dec 1997 A
5697967 Dinh et al. Dec 1997 A
5697971 Fischell et al. Dec 1997 A
5700286 Tartaglia et al. Dec 1997 A
5707385 Williams Jan 1998 A
5713949 Jayaraman Feb 1998 A
5716981 Hunter et al. Feb 1998 A
5722979 Kusleika Mar 1998 A
5725548 Jayaraman Mar 1998 A
5725549 Lam Mar 1998 A
5725567 Wolff et al. Mar 1998 A
5728150 McDonald et al. Mar 1998 A
5728420 Keogh Mar 1998 A
5733327 Igaki et al. Mar 1998 A
5733330 Cox Mar 1998 A
5733925 Kunz et al. Mar 1998 A
5735897 Buirge Apr 1998 A
5741293 Wijay Apr 1998 A
5744460 Muller et al. Apr 1998 A
5755772 Evans et al. May 1998 A
5759192 Saunders Jun 1998 A
5766239 Cox Jun 1998 A
5769883 Buscemi et al. Jun 1998 A
5770609 Grainger et al. Jun 1998 A
5773479 Grainger et al. Jun 1998 A
5776162 Kleshinski Jul 1998 A
5776181 Lee et al. Jul 1998 A
5776184 Tuch Jul 1998 A
5782908 Cahalan et al. Jul 1998 A
5788979 Alt et al. Aug 1998 A
5792106 Mische Aug 1998 A
5797898 Santini et al. Aug 1998 A
5799384 Schwartz et al. Sep 1998 A
5800507 Schwartz Sep 1998 A
5807404 Richter Sep 1998 A
5811447 Kunz et al. Sep 1998 A
5817152 Birdsall et al. Oct 1998 A
5820917 Tuch Oct 1998 A
5820918 Ronan et al. Oct 1998 A
5824045 Alt Oct 1998 A
5824048 Tuch Oct 1998 A
5824049 Ragheb et al. Oct 1998 A
5827322 Williams Oct 1998 A
5833651 Donovan et al. Nov 1998 A
5837008 Berg et al. Nov 1998 A
5837313 Ding et al. Nov 1998 A
5843117 Alt et al. Dec 1998 A
5843120 Israel et al. Dec 1998 A
5843166 Lentz et al. Dec 1998 A
5843172 Yan Dec 1998 A
5843175 Frantzen Dec 1998 A
5843741 Wong et al. Dec 1998 A
5849034 Schwartz Dec 1998 A
5851217 Wolff et al. Dec 1998 A
5851231 Wolff et al. Dec 1998 A
5853419 Imran Dec 1998 A
5855600 Alt Jan 1999 A
5865814 Tuch Feb 1999 A
5868781 Killion Feb 1999 A
5871535 Wolff et al. Feb 1999 A
5876419 Carpenter et al. Mar 1999 A
5879370 Fischell et al. Mar 1999 A
5879697 Ding et al. Mar 1999 A
5882335 Leone et al. Mar 1999 A
5886026 Hunter et al. Mar 1999 A
5891108 Leone et al. Apr 1999 A
5893840 Hull et al. Apr 1999 A
5902332 Schatz May 1999 A
5922020 Klein et al. Jul 1999 A
5922021 Jang Jul 1999 A
5928916 Keogh Jul 1999 A
5932243 Fricker et al. Aug 1999 A
5935506 Schmitz et al. Aug 1999 A
5945456 Grainger et al. Aug 1999 A
5948016 Jang Sep 1999 A
5954743 Jang Sep 1999 A
5957971 Schwartz Sep 1999 A
5964798 Imran Oct 1999 A
5968091 Pinchuk et al. Oct 1999 A
5968092 Buscemi et al. Oct 1999 A
5972027 Johnson Oct 1999 A
5976182 Cox Nov 1999 A
5980551 Summers et al. Nov 1999 A
5980552 Pinchasic et al. Nov 1999 A
5980972 Ding Nov 1999 A
5981568 Kunz et al. Nov 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
5992769 Wise Nov 1999 A
5994341 Hunter et al. Nov 1999 A
6007517 Anderson Dec 1999 A
6015432 Rakos et al. Jan 2000 A
6017362 Lau Jan 2000 A
6017363 Hojeibane Jan 2000 A
6019789 Dinh et al. Feb 2000 A
6022371 Killion Feb 2000 A
6024740 Lesh et al. Feb 2000 A
6027526 Limon et al. Feb 2000 A
6030414 Taheri Feb 2000 A
6033433 Ehr et al. Mar 2000 A
6039756 Jang Mar 2000 A
6042606 Frantzen Mar 2000 A
6056722 Jayaraman May 2000 A
6063101 Jacobsen et al. May 2000 A
6071305 Brown et al. Jun 2000 A
6074659 Kunz et al. Jun 2000 A
6083258 Yadav Jul 2000 A
6086582 Altman et al. Jul 2000 A
6086604 Fischell et al. Jul 2000 A
6087479 Stamler et al. Jul 2000 A
6099561 Alt Aug 2000 A
6099562 Ding et al. Aug 2000 A
6117101 Diederich et al. Sep 2000 A
6120535 McDonald et al. Sep 2000 A
6120536 Ding et al. Sep 2000 A
6120847 Yang et al. Sep 2000 A
6121027 Clapper et al. Sep 2000 A
6123721 Jang Sep 2000 A
6123861 Santini et al. Sep 2000 A
6140127 Sprague Oct 2000 A
6152957 Jang Nov 2000 A
6153252 Hossainy et al. Nov 2000 A
6156062 McGuiness Dec 2000 A
6159488 Nagler et al. Dec 2000 A
6171609 Kunz Jan 2001 B1
6174326 Kitaoka et al. Jan 2001 B1
6193746 Strecker Feb 2001 B1
6200334 Jang Mar 2001 B1
6206914 Soykan et al. Mar 2001 B1
6206916 Furst Mar 2001 B1
6210429 Vardi et al. Apr 2001 B1
6231598 Berry et al. May 2001 B1
6231600 Zhong May 2001 B1
6235053 Jang May 2001 B1
6239118 Schatz et al. May 2001 B1
6240616 Yan Jun 2001 B1
6241760 Jang Jun 2001 B1
6241762 Shanley Jun 2001 B1
6245101 Drasler et al. Jun 2001 B1
6249952 Ding Jun 2001 B1
6254632 Wu et al. Jul 2001 B1
6261318 Lee et al. Jul 2001 B1
6268390 Kunz Jul 2001 B1
6273908 Ndondo-Lay Aug 2001 B1
6273910 Limon Aug 2001 B1
6273911 Cox et al. Aug 2001 B1
6273913 Wright et al. Aug 2001 B1
6280411 Lennox Aug 2001 B1
6287332 Bolz et al. Sep 2001 B1
6290673 Shanley Sep 2001 B1
6293967 Shanley Sep 2001 B1
6299604 Ragheb et al. Oct 2001 B1
6306166 Barry et al. Oct 2001 B1
6306421 Kunz et al. Oct 2001 B1
6309414 Rolando et al. Oct 2001 B1
6312459 Huang et al. Nov 2001 B1
6312460 Drasler et al. Nov 2001 B2
6325826 Vardi et al. Dec 2001 B1
6334870 Ehr et al. Jan 2002 B1
6338739 Datta et al. Jan 2002 B1
6358556 Ding et al. Mar 2002 B1
6358989 Kunz et al. Mar 2002 B1
6368346 Jadhav Apr 2002 B1
6369039 Palasis et al. Apr 2002 B1
6387124 Buscemi et al. May 2002 B1
6395326 Castro et al. May 2002 B1
6399144 Dinh et al. Jun 2002 B2
6403635 Kinsella et al. Jun 2002 B1
6409761 Jang Jun 2002 B1
6423092 Datta et al. Jul 2002 B2
6423345 Bernstein et al. Jul 2002 B2
6429232 Kinsella et al. Aug 2002 B1
6451051 Drasler et al. Sep 2002 B2
6461380 Cox Oct 2002 B1
6461631 Dunn et al. Oct 2002 B1
6468302 Cox et al. Oct 2002 B2
6475237 Drasler et al. Nov 2002 B2
6482810 Brem et al. Nov 2002 B1
6488703 Kveen et al. Dec 2002 B1
6491617 Ogle et al. Dec 2002 B1
6491666 Santini et al. Dec 2002 B1
6491938 Kunz et al. Dec 2002 B2
6497916 Taylor et al. Dec 2002 B1
6500859 Kinsella et al. Dec 2002 B2
6503954 Bhat et al. Jan 2003 B1
6506411 Hunter et al. Jan 2003 B2
6506437 Harish et al. Jan 2003 B1
6511505 Cox et al. Jan 2003 B2
6515009 Kunz et al. Feb 2003 B1
6528121 Ona et al. Mar 2003 B2
6530950 Alvarado et al. Mar 2003 B1
6530951 Bates et al. Mar 2003 B1
6533807 Wolinsky et al. Mar 2003 B2
6537256 Santini et al. Mar 2003 B2
6540774 Cox Apr 2003 B1
6544544 Hunter et al. Apr 2003 B2
6547817 Fischell et al. Apr 2003 B1
6551303 Van Tassel et al. Apr 2003 B1
6551838 Santini et al. Apr 2003 B2
6558733 Hossainy et al. May 2003 B1
6562065 Shanley May 2003 B1
6569441 Kunz et al. May 2003 B2
6569688 Sivan et al. May 2003 B2
6572642 Rinaldi et al. Jun 2003 B2
6585765 Hossainy et al. Jul 2003 B1
6585773 Xie Jul 2003 B1
6599314 Mathis Jul 2003 B2
6599928 Kunz et al. Jul 2003 B2
6602282 Yan Aug 2003 B1
6602284 Cox et al. Aug 2003 B2
6613084 Yang Sep 2003 B2
6616690 Rolando et al. Sep 2003 B2
6627246 Mehta et al. Sep 2003 B2
D480809 Seibold et al. Oct 2003 S
D481130 Seibold et al. Oct 2003 S
D481139 Seibold et al. Oct 2003 S
6638302 Curcio et al. Oct 2003 B1
6645547 Shekalim et al. Nov 2003 B1
6656162 Santini et al. Dec 2003 B2
6656217 Herzog, Jr. et al. Dec 2003 B1
6660034 Mandrusov et al. Dec 2003 B1
6663664 Pacetti Dec 2003 B1
6663881 Kunz et al. Dec 2003 B2
6673385 Ding et al. Jan 2004 B1
6679911 Burgermeister Jan 2004 B2
6682545 Kester Jan 2004 B1
6689390 Bernstein et al. Feb 2004 B2
6702850 Byun et al. Mar 2004 B1
6706061 Fischell et al. Mar 2004 B1
6712845 Hossainy Mar 2004 B2
6713119 Hossainy et al. Mar 2004 B2
6716240 Fischell et al. Apr 2004 B2
6716242 Altman Apr 2004 B1
6716442 Hunter et al. Apr 2004 B2
6716444 Castro et al. Apr 2004 B1
6720350 Kunz et al. Apr 2004 B2
6723119 Pinchasik et al. Apr 2004 B2
6723373 Narayanan et al. Apr 2004 B1
6730064 Ragheb et al. May 2004 B2
6730116 Wolinsky et al. May 2004 B1
6746773 Llanos et al. Jun 2004 B2
6753071 Pacetti Jun 2004 B1
6764507 Shanley Jul 2004 B2
6770088 Jang Aug 2004 B1
6773455 Allen et al. Aug 2004 B2
6780424 Claude Aug 2004 B2
6783543 Jang Aug 2004 B2
6783793 Hossainy et al. Aug 2004 B1
6790228 Hossainy et al. Sep 2004 B2
6818063 Kerrigan Nov 2004 B1
6846841 Hunter et al. Jan 2005 B2
6855770 Pinchuk et al. Feb 2005 B2
6860946 Hossainy et al. Mar 2005 B2
6861088 Weber et al. Mar 2005 B2
6869443 Buscemi et al. Mar 2005 B2
6887510 Villareal May 2005 B2
6890339 Sahatjian et al. May 2005 B2
6896965 Hossainy May 2005 B1
6908622 Barry et al. Jun 2005 B2
6908624 Hossainy et al. Jun 2005 B2
6939376 Shulze et al. Sep 2005 B2
6964680 Shanley Nov 2005 B2
7192438 Margolis Mar 2007 B2
7195628 Falkenberg Mar 2007 B2
7429268 Shanley et al. Sep 2008 B2
20010000802 Soykan et al. May 2001 A1
20010018469 Chen et al. Aug 2001 A1
20010027340 Wright et al. Oct 2001 A1
20010029351 Falotico et al. Oct 2001 A1
20010034363 Li et al. Oct 2001 A1
20010044648 Wolinsky et al. Nov 2001 A1
20020002400 Drasler et al. Jan 2002 A1
20020005206 Falotico et al. Jan 2002 A1
20020007209 De Scheerder et al. Jan 2002 A1
20020007213 Falotico et al. Jan 2002 A1
20020007214 Falotico Jan 2002 A1
20020007215 Falotico et al. Jan 2002 A1
20020016625 Falotico et al. Feb 2002 A1
20020022876 Richter et al. Feb 2002 A1
20020028243 Bates et al. Mar 2002 A1
20020032414 Ragheb et al. Mar 2002 A1
20020038145 Jang Mar 2002 A1
20020041931 Suntola et al. Apr 2002 A1
20020068969 Shanley et al. Jun 2002 A1
20020071902 Ding et al. Jun 2002 A1
20020072511 New et al. Jun 2002 A1
20020082679 Sirhan et al. Jun 2002 A1
20020082680 Shanley et al. Jun 2002 A1
20020082682 Barclay et al. Jun 2002 A1
20020094985 Herrmann et al. Jul 2002 A1
20020123801 Pacetti et al. Sep 2002 A1
20020127263 Carlyle et al. Sep 2002 A1
20020128704 Daum et al. Sep 2002 A1
20020142039 Claude Oct 2002 A1
20020155212 Hossainy Oct 2002 A1
20020193475 Hossainy et al. Dec 2002 A1
20020198593 Gomez et al. Dec 2002 A1
20030004141 Brown Jan 2003 A1
20030004564 Elkins et al. Jan 2003 A1
20030018083 Jerussi et al. Jan 2003 A1
20030028244 Bates et al. Feb 2003 A1
20030036794 Ragheb et al. Feb 2003 A1
20030050687 Schwade et al. Mar 2003 A1
20030060877 Falotico et al. Mar 2003 A1
20030068355 Shanley et al. Apr 2003 A1
20030069606 Girouard et al. Apr 2003 A1
20030077312 Schmulewicz et al. Apr 2003 A1
20030083646 Sirhan et al. May 2003 A1
20030086957 Hughes et al. May 2003 A1
20030088307 Shulze et al. May 2003 A1
20030100865 Santini et al. May 2003 A1
20030125803 Vallana et al. Jul 2003 A1
20030157241 Hossainy et al. Aug 2003 A1
20030176915 Wright et al. Sep 2003 A1
20030181973 Sahota Sep 2003 A1
20030199970 Shanley Oct 2003 A1
20030204239 Carlyle et al. Oct 2003 A1
20030216699 Falotico Nov 2003 A1
20040002753 Burgermeister et al. Jan 2004 A1
20040073296 Epstein et al. Apr 2004 A1
20040122505 Shanley Jun 2004 A1
20040122506 Shanley et al. Jun 2004 A1
20040127976 Diaz Jul 2004 A1
20040127977 Shanley Jul 2004 A1
20050059991 Shanley Mar 2005 A1
20050119720 Gale et al. Jun 2005 A1
20050137678 Varma Jun 2005 A1
20070067026 Shanley Mar 2007 A1
20080097579 Shanley et al. Apr 2008 A1
20080097583 Shanley et al. Apr 2008 A1
20080109071 Shanley May 2008 A1
20080243070 Shanley Oct 2008 A1
Foreign Referenced Citations (114)
Number Date Country
2234787 Apr 1998 CA
20200220 Apr 2002 DE
0 294 905 Dec 1988 EP
0 335 341 Oct 1989 EP
0364787 Apr 1990 EP
0 374 698 Jun 1990 EP
0 470 569 Feb 1992 EP
0 543 653 May 1993 EP
0540290 May 1993 EP
0 556 245 Oct 1993 EP
0 566 807 Oct 1993 EP
0 567 816 Nov 1993 EP
0 712 615 May 1996 EP
0 716 836 Jun 1996 EP
0 734 698 Oct 1996 EP
0734699 Oct 1996 EP
0 747 069 Dec 1996 EP
0 761 251 Mar 1997 EP
0 770 401 May 1997 EP
0807424 Nov 1997 EP
0 809 515 Dec 1997 EP
0828461 Mar 1998 EP
0 850 651 Jul 1998 EP
0 897 700 Feb 1999 EP
0 934 036 Aug 1999 EP
0 938 878 Sep 1999 EP
0 950 386 Oct 1999 EP
0 959 812 Dec 1999 EP
0 980 280 Feb 2000 EP
1132058 Sep 2001 EP
1172074 Jan 2002 EP
1 181 943 Feb 2002 EP
1 189 554 Mar 2002 EP
1 223 305 Jul 2002 EP
1222941 Jul 2002 EP
1 236 478 Sep 2002 EP
1 348 402 Oct 2003 EP
0979059 Mar 2004 EP
1 570 807 Sep 2005 EP
1277449 Jun 2006 EP
2 764 794 Dec 1998 FR
WO 9001969 Mar 1990 WO
WO 9013332 Nov 1990 WO
WO 9110424 Jul 1991 WO
WO 9111193 Aug 1991 WO
WO 9112779 Sep 1991 WO
WO 9200747 Jan 1992 WO
WO 9212717 Aug 1992 WO
WO 9215286 Sep 1992 WO
WO 9306792 Apr 1993 WO
WO 9311120 Jun 1993 WO
WO 9407529 Apr 1994 WO
WO 9413268 Jun 1994 WO
WO 9421308 Sep 1994 WO
WO 9424961 Nov 1994 WO
WO 9424962 Nov 1994 WO
WO 9503036 Feb 1995 WO
WO 9503795 Feb 1995 WO
WO 9503796 Feb 1995 WO
WO 9524908 Sep 1995 WO
WO-9603092 Feb 1996 WO
WO 9525176 Aug 1996 WO
WO 9629028 Sep 1996 WO
WO 9632907 Oct 1996 WO
WO-9704721 Feb 1997 WO
WO 9710011 Mar 1997 WO
WO 9733534 Sep 1997 WO
WO 9805270 Feb 1998 WO
WO 9808566 Mar 1998 WO
WO 9818407 May 1998 WO
WO 9819628 May 1998 WO
WO 9823228 Jun 1998 WO
WO 9823244 Jun 1998 WO
WO 9834669 Aug 1998 WO
WO 9836784 Aug 1998 WO
WO 9847447 Oct 1998 WO
WO 9856312 Dec 1998 WO
WO 9858600 Dec 1998 WO
WO 9916477 Apr 1999 WO
WO-9915108 Apr 1999 WO
WO-9916386 Apr 1999 WO
WO-9936002 Jul 1999 WO
WO 9944536 Sep 1999 WO
WO-9949928 Oct 1999 WO
WO 9955395 Nov 1999 WO
WO 0010613 Mar 2000 WO
WO 0010622 Mar 2000 WO
WO 0021584 Apr 2000 WO
WO 0027445 May 2000 WO
WO 0032255 Jun 2000 WO
WO 0045744 Aug 2000 WO
WO 0069368 Nov 2000 WO
WO-0071054 Nov 2000 WO
WO 0117577 Mar 2001 WO
WO 0145763 Jun 2001 WO
WO 0145862 Jun 2001 WO
WO 0149338 Jul 2001 WO
WO 0152915 Jul 2001 WO
WO 0187342 Nov 2001 WO
WO 0187376 Nov 2001 WO
WO 0217880 Mar 2002 WO
WO 0226162 Apr 2002 WO
WO-0226281 Apr 2002 WO
WO 0241931 May 2002 WO
WO 02060506 Aug 2002 WO
WO 02087586 Nov 2002 WO
WO 03007842 Jan 2003 WO
WO 03018083 Mar 2003 WO
WO 03047463 Jun 2003 WO
WO 03057218 Jul 2003 WO
WO 2004043511 May 2004 WO
WO 2005053937 Jun 2005 WO
WO 2005118971 Dec 2005 WO
WO 2006036319 Apr 2006 WO
Related Publications (1)
Number Date Country
20040193249 A1 Sep 2004 US
Provisional Applications (1)
Number Date Country
60079881 Mar 1998 US
Continuations (3)
Number Date Country
Parent 10231007 Aug 2002 US
Child 10824124 US
Parent 09649217 Aug 2000 US
Child 10231007 US
Parent 09183555 Oct 1998 US
Child 09649217 US